Put Options on DGX on 12/3/2018

Quest Diagnostics Incorporated (DGX) provides diagnostic testing information and services in the United States and internationally.

The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.

This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals.

Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for health care organizations and clinicians.

Last week, the company warned of lower revenue. Following the announcement shares sold off forming a bearish "flag." Lower share prices are expected. Shares were downgraded this morning.

We will be trading January 18th Put option

Last Trade: $88.57

Trading Range: $85.56 - $116.49

Trade Buy 1 January $90.00 Put at $4.00 For a net debit of $4.00 Profit/Loss Analysis Breakeven at $86.00 Maximum profit is unbounded Maximum loss is ($400.00) at strike of $90.00 Closing Summary Sold 1 January $90.00 Put at $10.00

Position closed on 12/27/2018 at price of $10.00 with a 150.00% gain in 24 days.

Updates

12/27/2018 9:41:05 AM

DGX January $90 Put sold for $10.00

Back to Portfolio